Next Article in Journal
Comparative Response of Brain to Chronic Hypoxia and Hyperoxia
Next Article in Special Issue
Chronic Δ9-THC Exposure Differently Affects Histone Modifications in the Adolescent and Adult Rat Brain
Previous Article in Journal
The Role of Focal Adhesion Kinase in Keratinocyte Fibrogenic Gene Expression
Previous Article in Special Issue
Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2017, 18(9), 1916; doi:10.3390/ijms18091916

The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models

1
Department of Biotechnology and Life Sciences (DBSV), University of Insubria, 21052 Busto Arsizio (VA), Italy
2
Zardi Gori Foundation, 20122 Milan, Italy
*
Author to whom correspondence should be addressed.
Received: 24 July 2017 / Revised: 22 August 2017 / Accepted: 4 September 2017 / Published: 7 September 2017
(This article belongs to the Special Issue Cannabinoid Signaling in Nervous System)
View Full-Text   |   Download PDF [236 KB, uploaded 7 September 2017]   |  

Abstract

Autism spectrum disorder (ASD) defines a group of neurodevelopmental disorders whose symptoms include impaired communication and social interaction with restricted or repetitive motor movements, frequently associated with general cognitive deficits. Although it is among the most severe chronic childhood disorders in terms of prevalence, morbidity, and impact to the society, no effective treatment for ASD is yet available, possibly because its neurobiological basis is not clearly understood hence specific drugs have not yet been developed. The endocannabinoid (EC) system represents a major neuromodulatory system involved in the regulation of emotional responses, behavioral reactivity to context, and social interaction. Furthermore, the EC system is also affected in conditions often present in subsets of patients diagnosed with ASD, such as seizures, anxiety, intellectual disabilities, and sleep pattern disturbances. Despite the indirect evidence suggestive of an involvement of the EC system in ASD, only a few studies have specifically addressed the role of the EC system in the context of ASD. This review describes the available data on the investigation of the presence of alterations of the EC system as well as the effects of its pharmacological manipulations in animal models of ASD-like behaviors. View Full-Text
Keywords: endocannabinoid system; anandamide; cannabinoid type 1 receptor; autism spectrum disorder; animal models endocannabinoid system; anandamide; cannabinoid type 1 receptor; autism spectrum disorder; animal models
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zamberletti, E.; Gabaglio, M.; Parolaro, D. The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models. Int. J. Mol. Sci. 2017, 18, 1916.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top